Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,608.50
Bid: 1,607.50
Ask: 1,608.50
Change: -158.00 (-8.94%)
Spread: 1.00 (0.062%)
Open: 1,616.50
High: 1,620.00
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

Wed, 01st May 2024 07:46

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

The Fed announces its latest interest rate decision at 1900 BST. It is expected to keep rates on hold this week, with Chair Jerome Powell likely to say that the central bank is not yet confident enough to cut as inflation remains lofty.

Powell is expected to sound hawkish in a subsequent press conference following the decision.

"With the markets so bearishly positioned, there's a chance stocks could surge higher on Wednesday if the Fed sticks to their steady state, more so if investors are prepared to engage in a 'buy-the-fact' dynamic when Powell takes centre stage," SPI Asset Management analyst Stephen Innes commented.

"While risks around the Fed's mandate may appear more balanced now compared to the peak of the inflation scare, recent core price growth readings emphasize that inflation remains a primary concern, overshadowing worries about other economic indicators, so there is room for hawks to fly."

In early UK corporate news, GSK lifted its outlook, while Haleon affirmed guidance. Next said its first-quarter went better than planned, but expects a "weaker" second-quarter.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up slightly at 8,146.13

----------

Hang Seng: financial markets in Hong Kong closed

Nikkei 225: down 0.3% at 38,274.05

S&P/ASX 200: down 1.2% at 7,569.90

----------

Dow: closed down 570.17 points, 1.5%, at 37,815.92

S&P 500: closed down 1.6% at 5,035.69

Nasdaq Composite: closed down 2.0% at 15,657.82

----------

EUR: down at USD1.0657 (USD1.0690)

GBP: down at USD1.2479 (USD1.2523)

USD: up at JPY157.87 (JPY157.44)

GOLD: down at USD2,288.56 per ounce (USD2,298.10)

(Brent): down at USD85.48 a barrel (USD86.42)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

China - Labor Day. Financial markets closed.

France - Labor Day. Financial markets closed.

Germany - Labor Day. Financial markets closed.

Ireland - Labor Day. Financial markets closed.

Italy - Labor Day. Financial markets closed.

Spain - Labor Day. Financial markets closed.

Switzerland - Labor Day. Financial markets closed.

09:30 BST UK manufacturing PMI

11:00 BST Ireland unemployment

13:15 BST US ADP jobs report

14:45 BST US manufacturing PMI

15:00 BST US ISM manufacturing PMI

15:00 BST US job openings and labour turnover survey

19:00 BST US interest rate decision

----------

UK house price growth slowed last month, numbers from Nationwide showed. UK house prices rose 0.6% on-year in April, easing from a 1.6% surge in March. On a monthly basis, they fell 0.4%. They had declined 0.2% in March from February. "UK house prices fell by 0.4% in April, after taking account of seasonal effects. This resulted in a slowing in the annual rate of house price growth to 0.6% in April, from 1.6% the previous month," Nationwide analyst Robert Gardner said. "The slowdown likely reflects ongoing affordability pressures, with longer term interest rates rising in recent months, reversing the steep fall seen around the turn of the year. House prices are now around 4% below the all-time highs recorded in the summer of 2022, after taking account of seasonal effects."

----------

Politicians and canvassers are beginning their final day of campaigning ahead of Thursday's local elections in the UK. Voters in England and Wales will go to the polls on May 2 for local, mayoral, and police and crime commissioner elections. The polls are the final test of public opinion at the ballot box ahead of the next general election, which Prime Minister Rishi Sunak has said will come in the second half of 2024. Forecasts suggest the elections could see the Conservatives lose up to half of the council seats they are defending across 107 councils, having lost a third of seats last year. Most of the seats up for re-election were last contested in 2021, at the peak of Boris Johnson's popularity as the Covid-19 vaccine was rolled out. A total of 11 mayoral contests are also taking place, including for the London mayoralty. A wave of defeats for Sunak could be enough to push more Tory MPs into seeking to replace him as leader before the general election, though all counts will not be declared until Sunday, May 5.

----------

BROKER RATING CHANGES

----------

Berenberg raises FirstGroup price target to 195 (191) pence - 'buy'

----------

Berenberg raises HSBC price target to 830 (800) pence - 'buy'

----------

COMPANIES - FTSE 100

----------

Pharmaceutical firm GSK said it expects annual sales to rise at the upper end of its forecast, following a "strong" start to 2024. GSK said revenue in the first-quarter of the year rose 5.9% to GBP7.36 billion from GBP6.95 billion a year prior. Pretax profit, however, weakened 29% to GBP1.36 billion from GBP1.91 billion. GSK reported 'other' expenses worth GBP533 million, hurting its bottom line, and swing from GBP297 million in gains a year prior. Chief Executive Officer Emma Walmsley said: "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines. These, together with other R&D achievements, mean we have strengthened prospects for growth in all of our key therapeutic areas this quarter: infectious diseases, HIV, respiratory/immunology and oncology. We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024." GSK now expects annual revenue to rise at the upper part of its 5% to 7% range, at constant currency. It expects constant currency operating profit growth in its core operations of 9% to 11%, its outlook raised from 7% to 10%. Core earnings per share growth of 8% to 10% at constant currency is now expected, the guidance bumped up from 6% to 9%.

----------

Haleon, a consumer health arm spun out of GSK, backed its annual guidance and reported a "solid" quarter. Reported revenue declined 2.2% on-year to GBP2.92 billion in the first-quarter of the year. Revenue rose 3.0% on an organic basis, however. Pretax profit grew 8.9% to GBP590 million from GBP542 million. Looking ahead, it still predicts annual organic revenue growth in the 4% to 6% range. CEO Brian McNamara said: "First quarter trading was solid and in line with guidance shared when we reported FY 2023 results. Organic revenue growth of 3.0% was impacted by lapping tough comparatives in the prior year particularly in respiratory health and pain relief." The CEO added: "Regionally, whilst growth was held back in the US from inventory adjustments by some retailers, Haleon's consumption in this region was strong, up mid-single digit and ahead of the market. As such, we remain confident of delivering on our FY guidance."

----------

Retailer Next said sales in recent weeks have been ahead of expectations, and it maintained its annual profit forecast. In the 13 weeks to April 27, its first-quarter, full price sales rose 5.7% on-year. The outcome was ahead of guidance, with the clothing and homewares seller having predicted growth of 5%. It still expects pretax profit to grow 4.6% in the full-year to GBP960 million. Next added: "We are maintaining our guidance for full price sales in the first half to be up 2.5%. This implies that our sales in Q2 will be down -0.3%. We expect the sales performance in the second quarter to be weaker than the first quarter because last year benefited from particularly warm weather from late May through to the end of June."

----------

COMPANIES - FTSE 250

----------

Aston Martin Lagonda recorded weaker results, for a first-quarter that it labelled a "period of transition". The carmaker said revenue in the first-quarter fell 10% to GBP267.7 million from GBP295.9 million a year earlier. Its pretax loss widened to GBP138.8 million from GBP74.2 million. Executive Chair Lawrence Stroll commented: "2024 is a year of immense product transformation at Aston Martin, with the introduction of four new models to the market before the end of the year. Our first quarter performance reflects this expected period of transition, as we ceased production and delivery of our outgoing core models ahead of the ramp up in production of the new Vantage, upgraded DBX707 and our upcoming V12 flagship sports car which we've confirmed today. As part of our ongoing programme of ultra-exclusive models, we will deliver a new Special in the fourth quarter of the year." It expects a second-quarter performance to be "broadly similar" to the first. Stroll added: "In March, we were pleased to successfully complete our planned refinancing, securing improved terms on new five-year senior secured notes. This followed upgrades from leading credit agencies, recognising the significant progress made by Aston Martin over recent years and the opportunity for our strategy to continue to deliver improved performance in the years to come. This, along with our existing lenders demonstrating their continued support through a 70% increase in the new [revolving credit facility] to GBP170 million, marked a significant step in strengthening our balance sheet, aligning Aston Martin for a positive financial future." Net debt as of March 31 stood at GBP1.04 billion, rising 20% from GBP868.1 million a year prior.

----------

Computacenter said its first-quarter went largely in line with expectations, though it noted a "challenging" period in the UK. The technology and IT service provider expects adjusted pretax profit in the first-half to be weaker than the prior year's GBP121.8 million. Computacenter said: "Computacenter expects to make further progress in 2024 with the performance for the group during the first quarter broadly in line with our expectations. Germany and North America delivered solid underlying performances while the UK remained challenging."

----------

OTHER COMPANIES

----------

Luxury brand Mulberry expects to report an annual revenue decline, as it grappled with a "backdrop of challenging macro-economic conditions". Group revenue for the year ended March 30 fell 4%, or 2.7% at constant currency, it said. "While we achieved positive revenue growth in the first half, Mulberry has not been immune to the broader downturn in luxury spending experienced in recent months, particularly in the UK and Asia. This decline was partially offset by positive trading in the US, where we have benefitted from increased brand awareness," CEO Thierry Andretta said. "Looking ahead, the trading environment in the UK and China remains challenging and we do not expect this to change in the short term. We are therefore managing the business prudently, focusing on executing our strategy and vision to become a global sustainable luxury brand."

----------

Renold won a GBP10.6 million deal to produce flexible couplings for the Royal Canadian Navy. "This contract, together with other military work recently awarded, means that Renold's military order book has increased by GBP13.1 million, over recent months," the supplier of industrial chains and related power transmission products said. Renold explained the new pact with be delivered over the next six years. Flexible couplings are a key component on a ship's propulsion system, the firm said.

----------

Touchstone Exploration said it has struck an all-share deal to acquire Trinity Exploration & Production. The all-share agreement values the latter at GBP24.1 million. Touchstone Exploration, oil and natural gas exploration and production active in Trinidad & Tobago, said the deal will create a "leading Trinidadian operator of scale". It said: "The addition of Trinity's existing production portfolio, along with its exploration and development assets, will position the combined group as one of the leading independent operating companies dedicated to investing in both onshore and offshore activity to grow Trinidadian oil and gas production." As part of the deal, Trinity shareholders will receive 1.5 new Touchstone shares for each Trinity share owned. Trinity Shareholders will own just under 20% of the combined firm. Trinity directors consider the terms of the deal to be "fair and reasonable".

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.